Ito H, Hamano K, Fukumoto T, Wood K J, Esato K
First Department of Surgery, Yamaguchi University School of Medicine, Ube, Japan.
J Heart Lung Transplant. 1998 May;17(5):460-9.
Anti-CD4 monoclonal antibodies (mabs) are powerful immunosuppressive agents. However, in experimental models anti-CD4 treatment alone is not always completely effective. Anti-major histocompatibility complex (MHC) class II mabs may have a synergistic effect with anti-CD4 mab therapy by blocking the function of both antigen-presenting cells and T cells.
C3H/He mice (H-2k: I-Ak, I-Ek) received a vascularized cardiac graft from C57BL/10 (H-2b: I-Ab) or BALB/c (H-2d: I-Ad, I-Ed) mice and were treated with a depleting anti-CD4 or a depleting anti-MHC class II antibody either alone or in combination.
Anti-CD4 treatment alone prolonged graft survival in both strain combinations but was only minimally effective when BALB/c donors were used. However, when anti-CD4 and anti-MHC class II mabs were administered together, graft survival was significantly prolonged in both strain combinations. The ratio of interleukin-4 (IL-4)/interferon-gamma (IFN-gamma) expressed in both C57BL/10- and BALB/c-transplanted hearts 7 days after transplantation was significantly higher after combined treatment with anti-CD4 plus anti-MHC class II mabs compared with that found after either treatment alone. Twenty-one days after transplantation, the ratio of IL-4/IFN-gamma in BALB/c hearts after combined mab therapy was significantly lower than at 7 days after transplantation, but in contrast, the cytokine ratio in C57BL/10 hearts remained at an elevated level during the first 21 days after transplantation.
These data demonstrate that bidirectional blockade of the antigen-presenting cell and T-cell interaction by use of anti-CD4 and anti-MHC class II mabs in combination is more effective than either treatment alone. Graft survival in this model seems to correlate with a prolonged elevation of the IL-4/IFN-gamma ratio in the transplanted heart, suggesting that in this model the induction of unresponsiveness may be associated with a shift toward a Th2-type T-cell response.
抗CD4单克隆抗体(mabs)是强大的免疫抑制剂。然而,在实验模型中,单独使用抗CD4治疗并不总是完全有效。抗主要组织相容性复合体(MHC)II类单克隆抗体可能通过阻断抗原呈递细胞和T细胞的功能,与抗CD4单克隆抗体治疗产生协同作用。
C3H/He小鼠(H-2k:I-Ak,I-Ek)接受来自C57BL/10(H-2b:I-Ab)或BALB/c(H-2d:I-Ad,I-Ed)小鼠的带血管心脏移植,并单独或联合使用耗竭性抗CD4或耗竭性抗MHC II类抗体进行治疗。
单独使用抗CD4治疗在两种品系组合中均延长了移植物存活时间,但在使用BALB/c供体时效果甚微。然而,当同时给予抗CD4和抗MHC II类单克隆抗体时,两种品系组合中的移植物存活时间均显著延长。与单独使用任一治疗相比,抗CD4加抗MHC II类单克隆抗体联合治疗后,移植后7天在C57BL/10和BALB/c移植心脏中表达的白细胞介素-4(IL-4)/干扰素-γ(IFN-γ)比值显著更高。移植后21天,联合单克隆抗体治疗后BALB/c心脏中的IL-4/IFN-γ比值显著低于移植后7天,但相比之下,C57BL/10心脏中的细胞因子比值在移植后的前21天保持在升高水平。
这些数据表明,联合使用抗CD4和抗MHC II类单克隆抗体对抗原呈递细胞和T细胞相互作用进行双向阻断比单独使用任一治疗更有效。该模型中的移植物存活似乎与移植心脏中IL-4/IFN-γ比值的长期升高相关,表明在该模型中无反应性的诱导可能与向Th2型T细胞反应的转变有关。